Manufacturing: Page
-
Courtesy of Lonza Ltd.
Deep DiveVaccines can end the coronavirus pandemic. Will every country get them?
Scientists around the world are racing to develop a coronavirus vaccine. But the factories slated to make the leading candidates are concentrated in a handful of countries, raising concerns about global access.
By Jonathan Gardner • June 23, 2020 -
Craighead, Shealah. (2020). "President Trump Delivers an Update on Vaccine Development" [Photograph]. Retrieved from Flickr.
'Warp Speed' plan for coronavirus vaccines comes into focus
Developers backed by the project will get preferential access to manufacturing and distribution capacity secured by the U.S. government.
By Ned Pagliarulo • June 17, 2020 -
Permission granted by BioNTech SE
EU proposes countries band together to buy coronavirus vaccines
The European Union plans to spend billions from an emergency fund to make advanced purchases of coronavirus vaccines for its member states.
By Kristin Jensen • June 17, 2020 -
Sanofi's latest investment signals long-term focus on vaccines
The new coronavirus has brought a renewed interest in vaccines. Now, Sanofi plans to spend hundreds of millions of dollars preparing for future pandemics.
By Jacob Bell • June 16, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
AstraZeneca signs new supply deals as coronavirus vaccine data nears
The drugmaker agreed to provide 400 million doses to four European countries as part of preparations to supply the world with the coronavirus vaccine it licensed from the University of Oxford.
By Ben Fidler • June 15, 2020 -
Courtesy of FujiFilm
Fujifilm to invest nearly $1B in Denmark biologics plant
The Japanese contract manufacturer will double capacity at a biologics plant formerly owned by Biogen.
By Kristin Jensen • June 10, 2020 -
UPS expands healthcare business, shifting focus to vaccines
The coronavirus pandemic has forced the carrier to adjust and focus more heavily on the shipping and distribution of potential vaccines and treatments.
By Matt Leonard • June 10, 2020 -
US invests in drug vials to support coronavirus vaccine push
Through BARDA, the U.S. government will spend nearly $350 million to help two vial manufacturers dramatically scale up production.
By Ned Pagliarulo • June 9, 2020 -
AstraZeneca reaches deals with health charities to supply coronavirus vaccine worldwide
A separate agreement with India's Serum Institute aims to provide 1 billion doses of the experimental vaccine to low- and middle-income countries.
By Jonathan Gardner • June 4, 2020 -
Courtesy of Novavax, Australian Broadcasting Corporation
Novavax taps AGC Biologics to aid in production of COVID-19 vaccine
Like its larger rivals, the Maryland company is trying to add manufacturing capacity for its experimental coronavirus vaccine as quickly as possible.
By Kristin Jensen • June 4, 2020 -
US government promises Maryland drug manufacturer $628M to make coronavirus vaccines
The cash will secure manufacturing capacity at three Emergent sites for coronavirus vaccine developers, part of a sweeping government-led effort to make a protective treatment available as soon as possible.
By Ned Pagliarulo • June 2, 2020 -
Permission granted by BioNTech SE
Facing vial shortage, pharmas explore workarounds for coronavirus vaccines
"There's not enough vials in the world," said AstraZeneca's CEO on Thursday. Procuring enough to hold the billions of vaccine doses needed is yet another headache for coronavirus drugmakers to solve.
By Ned Pagliarulo • May 28, 2020 -
Jacob Bell/BioPharma Dive
Contaminated diabetes drugs raise red flag for FDA oversight
The Food and Drug Administration is reaching out to drug manufacturers after finding some metformin pills were contaminated with the carcinogen NDMA.
By Jacob Bell • Updated May 29, 2020 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158853/.
Novartis teams with Mass. Eye & Ear to join coronavirus vaccine chase
The Swiss pharma has become the latest large drugmaker to enter the worldwide race to develop a vaccine for COVID-19, tapping a project developed by gene therapy experts at the Massachusetts Eye and Ear Hospital.
By Jonathan Gardner • May 28, 2020 -
Courtesy of Novavax, Australian Broadcasting Corporation
Novavax buys more manufacturing capacity as first COVID-19 vaccine test begins
The Maryland biopharma has acquired a Czech vaccine developer for $167 million, gaining a facility in Europe that will boost its COVID-19 vaccine production capabilities.
By Kristin Jensen • May 28, 2020 -
How tariffs disrupted the COVID-19 medical supply chain
Months into the pandemic, the U.S. faces an ongoing shortage of PPE and some of it is still subject to tariffs.
By Deborah Abrams Kaplan • May 27, 2020 -
Permission granted by Gilead Sciences
Bangladesh pharma claims to be first to launch generic remdesivir
Beximco, which wasn't one of five drugmakers to license the coronavirus treatment from Gilead, says it can make a copycat version under World Trade Organization rules.
By Jonathan Gardner • May 21, 2020 -
Little-known drug manufacturer gets big contract for COVID-19 response
Through BARDA, the U.S. government has promised hundreds of millions of dollars to Phlow, a self-declared public benefit company that aims to secure a U.S.-based supply chain for essential medicines.
By Jacob Bell • May 19, 2020 -
Craighead, Shealah. (2020). "President Trump Delivers an Update on Vaccine Development" [Photograph]. Retrieved from Flickr.
'Operation Warp Speed,' unveiled by Trump, aims for coronavirus vaccine by year's end
Speeding the development and production of vaccines will be the project's principal aim, but it will also involve readying cold chain storage as well as supplies of needed vials and syringes.
By Ned Pagliarulo • May 15, 2020 -
Permission granted by Gilead Sciences
Gilead licenses COVID-19 drug to 5 generics companies
The agreements would allow Mylan, Cipla and others to make remdesivir and distribute it to 127 countries. A consumer advocacy group, though, criticized Gilead for leaving many countries out.
By Jacob Bell • May 13, 2020 -
Surprise setback for Bristol, Bluebird as FDA rejects cell therapy application
In a "refuse-to-file" letter, the regulator requested additional documentation of the companies' manufacturing processes for the CAR-T treatment, ide-cel.
By Ben Fidler , Ned Pagliarulo • May 13, 2020 -
Thermo Fisher to invest $180M in new gene therapy plant
The planned facility, to be built in Massachusetts, will rival in size a gene therapy plant in Texas owned by CDMO competitor Lonza.
By Kristin Jensen • May 13, 2020 -
Jacob Bell/BioPharma Dive
FDA, CDC drawing up plan to restart routine plant inspections
A phased approach is in the works to reintroduce oversight that's been on hold in the U.S. and abroad since March.
By Nick Paul Taylor • May 12, 2020 -
Permission granted by Gilead Sciences
Trump administration: States to decide which hospitals get Gilead's COVID-19 drug
HHS will distribute to states some of the roughly 600,000 vials of remdesivir Gilead is donating to the U.S., but said decisions on which hospitals receive the drug will be made by state health agencies.
By Ned Pagliarulo • May 11, 2020 -
Moderna plans earlier start to late-stage test of coronavirus vaccine
A Phase 3 trial of Moderna's experimental vaccine could begin in early summer, several months sooner than what was already an ambitious target for starting this fall.
By Ned Pagliarulo • May 7, 2020
Previous
